Last updated: 2026-02-08 04:50:23 ET
Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
Novo Nordisk and Eli Lilly fell after Hims & Hers said it will offer a copy of the Wegovy pill for $49, far less than the $149 Novo sells the branded pill for.
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.
The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry and faces lower prices for its medicines under a de...
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.
Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.
Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic r...
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling.
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
